VivoSeq
Infectious Disease

Multidrug-Resistant Tuberculosis

12

Pipeline Programs↗

4

Active Trials↗

7

Companies Involved↗

Multidrug-Resistant Tuberculosis is an emerging landscape with 12 programs across 7 companies. The most active players are Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Otsuka. 8 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

1 program

Phase 3K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 3Otsuka logo

Otsuka

3 programs

Phase 3Novartis logo

Novartis

1 program

ApprovedPfizer logo

Pfizer

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

9

clinical trials

Completed3 · 33%
Not yet recruiting2 · 22%
Unknown status2 · 22%
Active, not recruiting2 · 22%

Clinical Trials

Trial Activity

9 trials

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT03568383·5,832 enrolled
Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens
Active, not recruiting·HHarvard Medical School (HMS and HSDM)·N/A·NCT05871489·800 enrolled
Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment
Not yet recruiting·—·Phase 4·NCT07477119·150 enrolled
Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT07486024·55 enrolled
Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis
Completed·Otsuka logoOtsuka·Phase 3·NCT01424670·511 enrolled
A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)
Completed·Otsuka logoOtsuka·Phase 2·NCT00685360·481 enrolled
TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tuberculosis
Completed·Centers for Disease Control and Prevention·Preclinical·NCT00664313·36 enrolled
Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis
Unknown status·—·Phase 2·NCT05555303·20 enrolled
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
Unknown status·—·Phase 4·NCT05306223·212 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)